
|Videos|September 14, 2017
Remaining Questions With Multiple Myeloma Treatment
Author(s)Robert Orlowski, MD, PhD
Robert Orlowski, MD, PhD, Florence Maude Thomas Cancer Research professor and chair, ad interim, Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, discusses remaining questions with multiple myeloma treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
3
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5






































